Upload
abhishek2011g
View
229
Download
0
Embed Size (px)
Citation preview
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 1/27
Submitted By: Group – B7
Abhishek Gupta
Abhimanyu Jitani
Manojit Sasmal
REGENERON PHARMACEUTICALS
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 2/27
Table of Content
Chapter 1: Industry Overview ......................................................................................................... 3
1.1 What is Biotechnology? ........................................................................................................ 3
Chapter 2: Regeneron Pharmaceuticals .......................................................................................... 4
2.1 Introduction ........................................................................................................................... 4
2.2 History................................................................................................................................... 5
2.3 Regeneron Pharmaceuticals Vision ...................................................................................... 5
2.4 Regeneron Pharmaceuticals Mission .................................................................................... 6
2.5 Products................................................................................................................................. 6
Chapter 3: External Analysis .......................................................................................................... 8
3.1 PESTLE ANALYSIS ........................................................................................................... 8
3.2 Porter ’s Five Forces Model ................................................................................................. 10
Chapter 4: Internal Analysis ......................................................................................................... 13
4.1 SWOT Analysis .................................................................................................................. 13
4.2 Resources ............................................................................................................................ 14
4.2.1 Tangible Resources ...................................................................................................... 14
4.2.2 Intangible Resources .................................................................................................... 14
4.3 Core Competencies ............................................................................................................. 15
Chapter 5: Generic Strategy .......................................................................................................... 16
Chapter 6: Value chain of Regeneron Pharmaceuticals ................................................................ 17
Chapter 7: Strategic Approaches .................................................................................................. 19
7.1 Strategic Alliances .............................................................................................................. 19
7.2 Acquisition .......................................................................................................................... 19
Chapter 8: Regeneron Model (NPD) ............................................................................................ 20
Chapter 9: Regeneron Pharmaceuticals Business Model .............................................................. 22
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 3/27
Chapter 10: Code of Conduct ....................................................................................................... 24
10.1 Business Ethics ................................................................................................................. 24
10.2 Trading Securities on Inside Information ......................................................................... 24
10.3 Laws and regulations ........................................................................................................ 24
10.4 Anti-Trust Law.................................................................................................................. 25
Chapter 11: Future Growth Strategy ............................................................................................. 26
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 4/27
Chapter 1: Industry Overview
Biotechnology is the use of living systems and organisms to develop or make useful products, or
"any technological application that uses biological systems, living organisms or derivativesthereof, to make or modify products or processes for specific use".
1.1 What is Biotechnology?
At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular
and bio molecular processes to develop technologies and products that help improve our lives
and the health of our planet. We have used the biological processes of microorganisms for more
than 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy
products.
Modern biotechnology provides breakthrough products and technologies to combat debilitating
and rare diseases, reduce our environmental footprint, feed the hungry, and use less and cleaner
energy, and have safer, cleaner and more efficient industrial manufacturing processes.
Currently, there are more than 250 biotechnology health care products and vaccines available to
patients, many for previously untreatable diseases. More than 13.3 million farmers around the
world use agricultural biotechnology to increase yields, prevent damage from insects and pests
and reduce farming's impact on the environment. And more than 50 bio refineries are being built
across North America to test and refine technologies to produce biofuels and chemicals from
renewable biomass, which can help reduce greenhouse gas emissions.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 5/27
Chapter 2: Regeneron Pharmaceuticals
2.1 Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown,
in New York, US. The company was founded in 1988. Regeneron is a fully assimilated
biopharmaceutical company that discovers, develops, and market medicines for the treatment of
serious medical illnesses. Regeneron has the medicines which helped patients healing even in
Phase 3 clinical trials for the treatment of gout, eye diseases and certain cancers. Regeneron has
two products in development based on aflibercept, a VEGF inhibitor, and rilonacept,
an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels,
and interleukin-1 is a protein that is normally involved in inflammation.
Regeneron Pharmaceutical’s corporate headquarter and industry is located in New York. The
company has the revenue worth $1.4 billion and has a huge market share. Regeneron was
granted fundamental Patents rights by U.S. Patent and Trademark office for its Mouse Antibody
Technology used in Velocimmune. A similar European patent was granted by European Patent
office. Large- scale manufacturing is done at Regeneron and is performed under strict cGMP
(current Good Manufacturing Practices) conditions.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 6/27
2.2 History
By Abhishek Gupta
2.3 Regeneron Pharmaceuticals Vision
“Science to medicine”
Vision for Regeneron Pharmaceuticals remains static for the past ten year’s data. The vision of
this pharmaceutical company clearly states that the firm takes the help of all the possible
technologies in order to produce medicines which will help to cure serious medical conditions.
Their commitment towards the cutting edge science and enabling technologies helps the firm to
fully integrate into a biopharmaceutical enterprise:
VelociSuite Technologies Neurotrophins, cytokines, angiogenesis, receptor chemistry and signaling
Cytokine and growth factor traps
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 7/27
2.4 Regeneron Pharmaceuticals Mission
We can begin to see over the horizon to Regeneron in five or 10 years. What we see is a vibrant,
diversified biopharmaceutical company that addresses serious medical problems such as eye
diseases, hypercholesterolemia, rheumatoid arthritis and other inflammatory diseases, and
cancer.
2.5 Products
1. EYLEA – developed to treat a common cause of blindness in the elderly (Neovascular
age). The drug was approved by the U.S. Food and Drug Administration (FDA) in
November 2011. Eylea (aflibercept) is made from a human antibody fragment. It works
by keeping new blood vessels from forming under the retina (a sensory membrane that
lines the inside of the eye). In people with a certain type of eye disease, new blood
vessels grow under the retina where they leak blood and fluid. This is known as the "wet
form" of macular degeneration. Eylea is used to treat wet age-related macular
degeneration. Eylea is also used to treat swelling in the retina caused by a blockage in the
blood vessels.
2. ZALTRAP – Treating Metastatic colorectal cancer (Colon and rectal cancer involve the
lowest part of the digestive system). Approved by the FDA in August 2012. Zaltrap is a
medicine that contains the active substance aflibercept. It is available as a concentrate to
be made into a solution for infusion (drip) into a vein. The active substance in Zaltrap,
aflibercept, is a protein that binds to vascular endothelial growth factor (VEGF) and
placenta growth factor (PlGF), substances that circulate in the blood and makes blood
vessels grow. By binding to VEGF and PlGF, aflibercept stops them having an effect. As
a result, the cancer cells cannot develop their own blood supply and are starved of oxygen
and nutrients, helping to slow down the growth of tumors.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 8/27
3. ARCALYST – Approved by the FDA in February 2008. Arcalyst (rilonacept) is used to
treat some of the symptoms of rare genetic conditions such as Familial Cold Auto-
inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS). FCAS and MWS
are inflammatory disorders in which the body develops certain symptoms without a
known cause (such as virus, bacteria, or illness). These symptoms include fever, chills,
fatigue, and joint pain. More serious symptoms may involve the bones and joints, the
central nervous system (deafness, vision loss, mental impairment), or major organs such
as the kidneys. Arcalyst may treat or prevent the symptoms of Familial Cold Auto-
inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS). However, this
medication is not a cure for these inherited conditions.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 9/27
Chapter 3: External Analysis
3.1 PESTLE ANALYSIS
Many businesses fail to take the time to look at the macro and the micro environments when
completing their business plans and strategies. These external forces play a big part in shaping
the final outcome of the ultimate corporate achievement. Yet, most managers’ focus only on
internal factors and it is fair to say that sales growth and profits remain high on their agenda.
The macro environment tends to have a long term impact and requires extensive research. Below
is the PESTLE analysis for the pharmaceutical industry.
Political
There is a growing political focus and pressure on healthcare authorities across the world. This
means that governments look for savings across the board.
Economic
The global economic crisis still exists yet government reports show that they still spend on
healthcare per capital continues to grow. The growth in healthcare demonstrates how nursing
services have moved to the private sector and have become a key business offering. The
reduction in consumer disposable income will have an impact on those countries using health
insurance models particularly where part payment is required.
These economic pressures are seeing an increased growth in strategic buying groups who areforcing down prices. Increased pressure from shareholders has caused a consolidation of the
industry: more mergers and acquisitions will take place over the coming years.
Social
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 10/27
The increasing aging population offers a range of opportunities and threats to the pharmaceutical
industry. The purpose is to Capitalize on the opportunities. There is also the problem of the
increasing obesity amongst the population and its associated health risks. Patients and home
carriers are becoming more informed. Their expectations have changed and they have become
more demanding. Public activism (e.g. PETA activists) has also increased through the harnessing
of new social networking technologies
Technological
Technological advancements will create new business prospects both in terms of new therapy
systems and service provisions. Development of molecules as resulting from technology
changes. The online opportunities will see the growth in new information and Communications
technologies.
Social Media for Healthcare
Customized Treatments
Direct to Patient Advertising
Direct to patient communications
LegislationThe pharmaceutical industry has many regulatory and legislative restrictions. There is also a
growing culture of litigation in many countries. The evolution of the internet is also stretching
the legislative boundaries with patient’s demanding more rights in their healthcare programs.
Environmental
There is a growing environmental agenda and the key stake holders are now becoming more
aware of the need for businesses to be more proactive in this field. Pharmaceutical companies
need to see how their business and marketing plans link in with the environmental issues. There
is also an opportunity to incorporate it within their Corporate Social Responsibility programs.
Marketing and new product development should identify eco opportunities to promote as well.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 11/27
3.2 Porter’s Five Forces Model
1. Threats of New Entrant – LOW:
High barriers to entry as the company needs to put a lot of capital into research and development,
lengthy approval process, marketing before it is able to receive any returns. The “big
pharmaceutical” companies that were able to build global operations are benefiting from
economies of scale in terms of manufacturing. They are able to access low-cost supplies, as a
result. Challenging regulatory conditions (hurdles to get FDA drug approvals for new products);
industry is highly regulated which to some extend protects from new competition. The FDA
approvals appear to have slowed during 2007. This could be one measure indicating that the
FDA is taking a more cautious position on new drug approvals. In addition, legislative changes
in the upcoming years may have a negative impact for the industry. Pharmaceutical companies
benefit from continuation of U.S. employer-based health coverage. Customers buy medicationthat was prescribed by the doctors. Patent expirations may lead to an entry of new competitors
(generic competitions), resulting in decreased revenues. High rates of patent expirations are
approaching in 2010 through 2012. The ability of a pharmaceutical company to offset loss of
revenue from patent expirations depends on growth in existing products as well as successful
execution from the new product pipeline.
2. Rivalry among existing firms – HIGH:
The pharmaceutical industry is the highly competitive market as there a big players that are
influencing the whole industry. The industries like Pfizer, Johnson & Johnson, Roche, &
GlaxoSmithKline comprises of majority of market share. Industry benefits from strong demand
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 12/27
from consumers. Weak, small companies usually go out of business (bankruptcy) if they have no
potential “blockbuster” in future pipeline. Others that have some significant research or valuable
assets will be bought by big and strong pharmaceutical companies.
3. Bargaining power of suppliers – HIGH:
In the case of pharmaceutical suppliers they have a better chance to bargain as the patents for
drugs are very highly priced and so negotiations are high. Also, the suppliers need patent licenses
for the manufacturing of goods which could come at a high cost and thus they charge more for
their product from pharmaceutical companies.
4. Bargaining power of buyers – LOW:
Generally consumers have very little bargaining power. Most of the medication is prescribed by
the doctors. Consumers will have to buy the drug at any given price if they need it. More
educated consumers may buy a generic alternative (which have the same impact but less
expensive) if available on the market.
Pricing pressure – The U.S. remains one of the few developed markets where drug
manufacturers have significant pricing flexibility, and this is in jeopardy due to increasing
pressures from consumers and legislators to control health care costs. Governments in other
markets are generally the primary customers, and therefore, enjoy substantial pricing leverage.
Shareholders continue to pressure the companies for increases in the share repurchase programs.
The companies looking for ways to increase shareholders returns partly because the industry is
approaching maturity and is not growing as rapidly, and because many companies have a lot of
cash on their balance sheet.
5. Threat of Substitute – MEDIUM:
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 13/27
Threat from generic competition. Customers can find substitute medicine if the original product
has an expired patent. However, if it is a new product the consumer generally will have no
choice for an alternative. Over the few years generic drug manufacturers face excellent
opportunities for utilization and volume trends. Generic companies are increasing focused on
establishing global operations in order to achieve a lower-cost of supplies, thus posing even more
threat to non-generic drug manufacturers.
Based on Porter’s model LOW to MEDIUM forces are present among the strong players in the
pharmaceutical industry. Thus, the industry is attractive to investors largely due to the high-
barriers to entry, purchasing and pricing power, and strong credit profiles of existing firms.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 14/27
Chapter 4: Internal Analysis
4.1 SWOT Analysis
Strengths
Technology and Innovation – Regeneron Pharmaceuticals has Velocimmune Technology
which is very advance as it is a mammal genetic engineering. This technology produces
fully human monoclonal antibodies based on mouse genetics.
Distribution Network – Regeneron Pharmaceuticals have a strong distribution network in
U.S. and to commercialize the product outside U.S they collaborated with Bayer’s
Healthcare to share their distribution network.
Experienced Management
Weaknesses
Research & Development – Their R&D competencies are very weak and to develop the
drug they made alliances with Sanofi – Aventis and Bayer’s Healthcare.
Opportunities
Medical Research for more critical diseases like HIV.
Growing Economy
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 15/27
Threats
Expiration of Patents – Patents lasts for 17 years and thus thereafter the drug can be
imitated by other pharmaceutical companies
Government Regulations – Every drug which is produced required permissions from
government regulatory authorities and there exist a threat of losing the whole research
and development on the drug if it is not approved by the authorities.
High competition – The market is dominated by large pharmaceutical companies like
Johnson & Johnson, Pfizer, Roche and GlaxoSmithKline.
4.2 Resources
4.2.1 Tangible Resources
Laboratories use cutting-edge analytical equipment, automated laboratory information
management systems, and electronic document management systems.
Fundamental Patents rights by U.S. Patent and Trademark office for its Mouse Antibody
Technology used in Velocimmune.
Manufacturing performed under strict cGMP (current Good Manufacturing Practices)
conditions.
4.2.2 Intangible Resources
Expertise of technical staff i.e. scientists, engineers, technicians, and managers for
developing and operating the complex manufacturing processes
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 16/27
4.3 Core Competencies
It is a skill or expertise that the organization possesses to gain a competitive advantage over its
competitors. It is performed better than other activities. Core competencies are not easy to
imitate and can be used for many products.
Innovation – Product idea generation and bringing these ideas into final drugs is the core
competency of Regeneron Pharmaceuticals. Drugs like Eylea is the biggest innovation
they made in collaboration with Sanofi – Aventis.
Velocimmune Technology (mammalian genetic engineering i.e. technology for producing
fully human monoclonal antibodies).
Regeneron has Expertise and knowledge in neurotropic factors and regenerative
capabilities.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 17/27
Chapter 5: Generic Strategy
Regeneron Pharmaceuticals is following focused differentiation strategy as it is catering to
specific diseases, selling to specific segment and charging premium prices. Regeneron is
following niche marketing strategy to gain the competitive advantage over its competitors. For
example, EYLEA is a drug for curing the blindness of old-age people thus, targeting the specificsegment of people.
A broad cross-section of buyers
A narrow
buyer segment(or market
niche)
Lower cost Differentiation
Best –
Cost
Provider
Strategy
Overall Low – Cost Provider
Strategy
BroadDifferentiation
Strategy
Focused Low
– Cost
Strategy
Focused
DifferentiationStrategy
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 18/27
Chapter 6: Value chain of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has a different value chain as compared to conventional value chain.
The components of value chain for Regeneron Pharmaceuticals are:
1. Discovery
2. Product Development
3. Manufacturing
4. Marketing
Regeneron is a vertically integrated firm as from the drug development to manufacturing and
distribution are done by the firm. Regeneron shares the Discovery stage with Sanofi-Aventis and
Bayer’s Healthcare and for distribution outside U.S. Regeneron was sharing Bayer’s Healthcare
distribution network.
Discovery
Regeneron brings the product ideas for critical and rare disease whose cure is not available in the
market. Then the research is performed for the feasibility of the drug which is shared with their
strategic partners to reduce the risks.
Product Development
Once the molecular discovery is completed, Regeneron moves towards the development stage in
which 3 stages testing’s are performed to check the compatibility of drugs on the human body.
Once all the 3 stages are successfully cleared, the drug is given to the regulatory authority for the
approval.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 19/27
Manufacturing
As soon as the approval is received, Regeneron starts producing the drug in their manufacturing
facilities i.e. the drug is produced in-house.
Marketing
Further the product is distributed through their distribution network in U.S. and to commercialize
the product outside U.S., Regeneron share the distribution of Bayer’s Healthcare.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 20/27
Chapter 7: Strategic Approaches
7.1 Strategic Alliances
I. In 2003 allied with Aventis to develop and commercialize VEGF Trap-eye which further
got merged with Sanofi
II. In 2006, allied with Bayer healthcare to develop and commercialize Eylea and support
VEGF-Trap
III. 2007, made partners with Sanofi & Aventis to discover and develop & commercialize
fully human antibodies
IV. In 2010 VEGF-Trap entered clinical trial.
7.2 Acquisition Acquired manufacturing facility in NY in 1993 to develop in-house capabilities and to
get vertically integrated.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 21/27
Chapter 8: Regeneron Model (NPD)
Regeneron Pharmaceuticals follows the model as shown in the figure below for new product
development. In this model, the firm first generate ideas about the drug to be developed and
according to the skills and competencies of their partners, they decide whom to choose for which
type of drug development. After selecting the partner for the drug, the drug is designed and
developed with the strategic partner. After the molecule for the drug is formed and researched,
the trials are performed for testing the drug. These trials are performed in 3 phases:
Trial 1
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 22/27
In this the drug is tested on the mouse using Velocimmune human antibodies technology to
check for any side – effects and whether the drug is working as per the plan.
Trial 2
This trial is performed on other animals to check whether the same results are achieved on them
or not.
Trial 3
This is the last trial which is termed as clinical trial. As this trial is done on the humans to check
the consistencies of the drug.
Once the unique and innovative drug passes through all the stages of trials, the drug is send for
approval from government regulatory authority. And after the approval is received, Regeneron
executes the production of the drug followed by the distribution.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 23/27
Chapter 9: Regeneron Pharmaceuticals Business Model
Regeneron core technology is Innovation as they have experienced staff and are good in bring
new ideas into existence. The firm shares their resources i.e. Velocimmune Technology –
monoclonal human antibodies which is mammal genetic engineering with their partners Sanofi –
Aventis and Bayers Healthcare in return by sharing the research and development with them to
bring new product idea into existence. They have two functionality in their organization which is
Drug Development and Production. The firm is vertically integrated and in these the drug
development is shared with their strategic alliances to share their risks and then the in – house
production of the government regulatory approved drug is done. They had made this
competencies by acquiring the manufacturing facilities in New York in 1993. Further the drug is
passed through quality check and then the packaging is done and the distribution of product is
made.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 24/27
In this distribution, the firm is having a good network in U.S but for the commercialization of
drugs outside U.S they are sharing the network with Bayer Healthcare. The revenue achieved
from the drug selling are further utilized in improving their in house R&D team, so that in future
they could have their own R&D.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 25/27
Chapter 10: Code of Conduct
10.1 Business Ethics
Regeneron business success and reputation are built upon the principles of fair dealing and
ethical conduct of all officers, directors, and employees. Regeneron continued success depends
upon the trust of their customers, collaborators, employees, shareholders, contractors, and
suppliers.
Regeneron policy is to comply with all applicable laws and regulations. Officers, directors, and
employees are expected to conduct business in accordance with all relevant laws, regulations,
and company policies and to refrain from any illegal, dishonest, or unethical conduct.
10.2 Trading Securities on Inside Information
Federal law and Regeneron policy prohibits officers, directors, and employees, directly or
indirectly through their families or others, from purchasing or selling Regeneron stock while in
the possession of material, non- public information concerning Regeneron. The same prohibition
applies to trading in the stock of other publicly held companies on the basis of material, non-
public information obtained from Regeneron. Regeneron has a specific policy on insider trading.
10.3 Laws and regulations
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 26/27
Regeneron expects all personnel to comply with all applicable laws and regulations. These
include, but are not limited to, False Claims Acts, Anti-Kickback Statutes, Prescription Drug
Marketing Act, Food and Drug Administration Modernization Act, Federal Food, Drug, and
Cosmetic Act, Health Insurance Portability and Accountability Act and Federal healthcare
program requirements. Violations of healthcare laws or regulations may result in severe
penalties against the responsible employees and the Company, including jail sentences, large
fines and exclusion of Regeneron products from reimbursement under federal and state
programs. Regeneron is committed to conducting the sales and marketing of its products in
compliance with these laws.
10.4 Anti-Trust Law
Regeneron understands that the public interest is best served by vigorous competition and will
suffer from illegal agreements or collusion among competitors. Compliance with applicable
competition and antitrust laws within in the United States and other countries in which the
Company does business is essential to Regeneron. Antitrust laws are complex and difficult to
interpret. Although not exhaustive, the following list provides a general guide to antitrust
compliance:
i. No employee, officer or director shall discuss with or provide information to any
competitor about pricing or related matters, whether such information concerns the
Company or Regeneron suppliers, distributors, wholesalers or customers.
ii. No employee, officer or director shall agree with a customer on resale price; imply that
such resale price is a condition of sale, contract renewal, or advertising allowance; or
discuss with or imply to a customer that Regeneron will attempt to influence the pricing
of another customer or competitor.
iii. No employee, officer or director shall engage in group boycotts or allocate or divide
customers, territories or production with a competitor.
7/21/2019 Regeneron Pharmaceuticals by Abhishek Gupta
http://slidepdf.com/reader/full/regeneron-pharmaceuticals-by-abhishek-gupta 27/27
iv. No employee, officer or director shall engage in any predatory pricing or discriminate in
prices or terms of sale, for like goods, between competing customers to the injury or
damage of the disfavored customers, or induce a seller to so discriminate in favor of the
Company, as purchaser.
Chapter 11: Future Growth Strategy
1. Regeneron Pharmaceuticals is developing 2 drugs for curing LDL cholesterol which is
the most common problem in the world and rheumatoid arthritis. On Nov 22, 2013Sarilumab drug which is used to treat rheumatoid arthritis reached its clinical stage of
testing.
2. Since Eylea sales continue to increase by 49% in U.S. and by 22.5% outside U.S. and
along with this the product is also used to cure small eye related disease that is caused
due to blood clotting, so the firm can spend further on the research and development of
Eylea to discover more about the other usability of the drug.
3. Regeneron can move their research & development into more critical drug whose cure is
not available like HIV.